Purple BiotechPPBT -0.59%25 Quick Ratio is 1.48 as of Mar. 2026, which is 46% below its 10-year median of 2.72. GuruFocus rates PPBT with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Purple Biotech ranks worse than 73.23% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Purple Biotech's quick ratio for the quarter that ended in Mar. 2026 was 1.48.
Purple Biotech has a quick ratio of 1.48. It generally indicates good short-term financial strength.
The historical rank and industry rank for Purple Biotech's Quick Ratio or its related term are showing as below:
PPBT'
s Quick Ratio Range Over the Past 10 Years
Min: 1.22 Med: 2.72 Max: 19.13
Current: 1.48
During the past 13 years, Purple Biotech's highest Quick Ratio was 19.13. The lowest was 1.22. And the median was 2.72.
PPBT's Quick Ratio is ranked worse than 73.23% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs PPBT: 1.48
Purple Biotech (NAS:PPBT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Purple Biotech Quick Ratio Related Terms
Purple Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for Purple Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Purple Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Purple Biotech Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Purple Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Purple Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Purple Biotech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Purple Biotech (PPBT) has a Quick Ratio of 1.48 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Purple Biotech and its competitors. This is 46% below median its historical median of 2.72. Over the past decade, Purple Biotech's Quick Ratio has ranged from 1.22 to 19.13. According to the industry distribution chart, Purple Biotech ranks #1034 out of 1412 companies in the Biotechnology industry, placing it in the top 73.2%.
Is Purple Biotech's Quick Ratio too high?
Purple Biotech's current Quick Ratio of 1.48 is 46% below median its 10-year median of 2.72. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 19.13. The Biotechnology industry median Quick Ratio is 3.60. Purple Biotech's value of 1.48 is 58.9% below this industry median. Based on the distribution chart, Purple Biotech ranks #1034 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Purple Biotech has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Purple Biotech ranks #1034 out of 1412 companies for Quick Ratio. This places Purple Biotech in the lower half of its industry. The industry median Quick Ratio is 3.60. Purple Biotech's value of 1.48 is 58.9% below this benchmark. Historically, Purple Biotech's own Quick Ratio has ranged from 1.22 to 19.13 over the past decade. While the company's 10-year median is 2.72 vs. the industry median of 3.60, Purple Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Purple Biotech's current Quick Ratio of 1.48 is 58.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Purple Biotech and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Purple Biotech's current Quick Ratio is 1.48, which is 46% below median its own 10-year median of 2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (PPBT) has a current Quick Ratio of 1.48. The current Quick Ratio is 1.48, which is 46% below median its 10-year median of 2.72 and 58.9% below the Biotechnology industry median of 3.60. Purple Biotech's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Purple Biotech (PPBT), the current Quick Ratio is 1.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
25GF Score
Get the complete analysis for PPBT
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PPBT has been successfully added to your 
